Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383930 | 0.89 | MAPK10 (0.61) | MAPK10MAPK9MAPK8 | |
| SCHEMBL5096760 | 0.83 | MAPK10 (0.64) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL4383934 | 0.82 | MAPK10 (0.60) | MAPK10MAPK9MAPK8 | |
| SCHEMBL5096754 | 0.81 | MAPK10 (0.67) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL1518698 | 0.81 | MAPK10 (1.00) | MAPK10MAPK9MAPK8HPGDALOX5 | |
| SCHEMBL5102944 | 0.81 | MAPK10 (0.74) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL5596927 | 0.80 | MAPK10 (0.67) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL5596240 | 0.79 | MAPK10 (0.78) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL2884876 | 0.78 | MAPK10 (0.79) | MAPK10MAPK9MAPK8HPGDCYP1A2 | |
| SCHEMBL7137698 | 0.78 | MAPK10 (0.62) | MAPK10MAPK9MAPK8HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | claimed |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-04-19 | — | — | US | claimed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| EP-1240164-A1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001047920-A1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | MAPK10 35/4885MAPK9 33/4885MAPK8 31/4885 |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MAPK10 3/4885MAPK9 28/4885MAPK8 12/4885 |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | GPR119, GLS2, GLS | MAPK10 3255/4885MAPK9 4264/4885MAPK8 3132/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK10 40/4885MAPK9 49/4885MAPK8 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.